BERG Announces Clinical Trial Data Presentations Of BPM 31510 In Advanced Solid Tumors And BPM

BERG will be presenting interim data from its ongoing Phase I study of BPM 31510 (IV) in advanced solid tumors, which demonstrates the promise of metabolically-driven therapy by reversing the Warburg phenotype in cancer. BPM 31510 (IV) is one of the first cancer drugs guided in development by artificial intelligence. BPM 31510 (IV) appears to reverse the compromised metabolism of cancer cells which normalizes the cancer microenvironment to induce cell death. BERG's Interrogative Biology platform was used in its BPM 31510 (IV) Phase I study to discover molecular markers identifying patients more likely to have clinical benefit to the treatment applying a precision medicine approach to the trial.